Suppr超能文献

间充质干细胞来源的细胞外囊泡:用于神经退行性疾病的新型治疗策略。

Extracellular Vesicles from Mesenchymal Stem Cells: Towards Novel Therapeutic Strategies for Neurodegenerative Diseases.

机构信息

Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.

Neurology Unit, Azienda Ospedaliera Universitaria Integrata Verona, 37124 Verona, Italy.

出版信息

Int J Mol Sci. 2023 Feb 2;24(3):2917. doi: 10.3390/ijms24032917.

Abstract

Neurodegenerative diseases are fatal disorders of the central nervous system (CNS) which currently lack effective treatments. The application of mesenchymal stem cells (MSCs) represents a new promising approach for treating these incurable disorders. Growing evidence suggest that the therapeutic effects of MSCs are due to the secretion of neurotrophic molecules through extracellular vesicles. The extracellular vesicles produced by MSCs (MSC-EVs) have valuable innate properties deriving from parental cells and could be exploited as cell-free treatments for many neurological diseases. In particular, thanks to their small size, they are able to overcome biological barriers and reach lesion sites inside the CNS. They have a considerable pharmacokinetic and safety profile, avoiding the critical issues related to the fate of cells following transplantation. This review discusses the therapeutic potential of MSC-EVs in the treatment of neurodegenerative diseases, focusing on the strategies to further enhance their beneficial effects such as tracking methods, bioengineering applications, with particular attention to intranasal delivery as a feasible strategy to deliver MSC-EVs directly to the CNS in an effective and minimally invasive way. Current progresses and limiting issues to the extent of the use of MSC-EVs treatment for human neurodegenerative diseases will be also revised.

摘要

神经退行性疾病是中枢神经系统(CNS)的致命性紊乱,目前缺乏有效的治疗方法。间充质干细胞(MSCs)的应用代表了治疗这些不治之症的一种新的有前途的方法。越来越多的证据表明,MSCs 的治疗效果是由于通过细胞外囊泡分泌神经营养分子。MSC 产生的细胞外囊泡(MSC-EVs)具有源自亲本细胞的有价值的固有特性,并可作为细胞游离治疗剂用于许多神经疾病。特别是,由于其体积小,它们能够克服生物屏障并到达 CNS 内的病变部位。它们具有相当大的药代动力学和安全性特征,避免了与细胞移植后命运相关的关键问题。本文讨论了 MSC-EVs 在治疗神经退行性疾病中的治疗潜力,重点讨论了进一步增强其有益效果的策略,例如跟踪方法、生物工程应用,特别关注鼻内给药作为一种将 MSC-EVs 直接有效且微创地递送至 CNS 的可行策略。还将审查 MSC-EVs 治疗人类神经退行性疾病的使用范围的当前进展和限制问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0cb/9917806/19a830427e23/ijms-24-02917-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验